Cargando…

ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation

BACKGROUND: Even though identical blood group matching between recipient and donor is preferred, it is still not clear by how much this improves the outcome for patients who received a lung transplant (LTx), or whether there is any survival benefit. Earlier studies have yielded ambiguous results and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakhro, Mohammed, Larsson, Hillevi, Malmsjö, Malin, Algotsson, Lars, Lindstedt, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350378/
https://www.ncbi.nlm.nih.gov/pubmed/30691526
http://dx.doi.org/10.1186/s13019-019-0846-6
_version_ 1783390442828595200
author Fakhro, Mohammed
Larsson, Hillevi
Malmsjö, Malin
Algotsson, Lars
Lindstedt, Sandra
author_facet Fakhro, Mohammed
Larsson, Hillevi
Malmsjö, Malin
Algotsson, Lars
Lindstedt, Sandra
author_sort Fakhro, Mohammed
collection PubMed
description BACKGROUND: Even though identical blood group matching between recipient and donor is preferred, it is still not clear by how much this improves the outcome for patients who received a lung transplant (LTx), or whether there is any survival benefit. Earlier studies have yielded ambiguous results and few have investigated long-term survival. The aim of this study is, therefore, to explore the different outcomes of identical and compatible recipient and donor blood group matching to determine whether identical matching is superior (LTx). METHOD: Between January 1990 to June 2016, 297 patients underwent primary LTx, 10 patients underwent heart and lung transplantation (HLTx), and 18 patients required re-transplantation (Re-LTx) at Skåne University Hospital in Lund. With a total of 325 transplantations at our center, 262 were ABO-identically matched while 53 were ABO-compatible. For survival analyses, the end-point used was retransplantation-free survival in addition to excluding HLTx (n = 10), assessed by Cox regression and Kaplan-Meier. RESULTS: ABO-compatible patients had a median of 49 days (2–641), and ABO-identical patients had a median of 89 days (1–1717) (p = 0.048) on the transplant waiting list. Patients with a limited survival up to 1-year showed significant difference in survival rate for ABO-compatible recipients compared to ABO-identical recipients (p < 0.05), however no significant difference was shown in overall survival between the two groups (p > 0.05), with the same pattern shown in patients with a limited survival rate up to ten years, emphysema-patients, when excluding single-LTx and patients transplanted before 2005 and after 2005, respectively (p > 0.05). CONCLUSION: Recipients who received ABO-compatible matched grafts showed a similar survival rate to recipients who received ABO-identical matched grafts in the present study. Cytolomegalovirus and Ebstein Barr Virus mismatch were also identified as risk factors particular among emphysema patients. Since ABO-identical transplantations and ABO-compatible transplantations showed similar results, the present selection-bias of preferring ABO-identical lungs could be adjusted to increase organ allocation. It might also be possible to shorten recipient waiting list time, as an identical match showed over 80% higher time on the waiting list than a compatible, non-identical match.
format Online
Article
Text
id pubmed-6350378
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63503782019-02-04 ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation Fakhro, Mohammed Larsson, Hillevi Malmsjö, Malin Algotsson, Lars Lindstedt, Sandra J Cardiothorac Surg Research Article BACKGROUND: Even though identical blood group matching between recipient and donor is preferred, it is still not clear by how much this improves the outcome for patients who received a lung transplant (LTx), or whether there is any survival benefit. Earlier studies have yielded ambiguous results and few have investigated long-term survival. The aim of this study is, therefore, to explore the different outcomes of identical and compatible recipient and donor blood group matching to determine whether identical matching is superior (LTx). METHOD: Between January 1990 to June 2016, 297 patients underwent primary LTx, 10 patients underwent heart and lung transplantation (HLTx), and 18 patients required re-transplantation (Re-LTx) at Skåne University Hospital in Lund. With a total of 325 transplantations at our center, 262 were ABO-identically matched while 53 were ABO-compatible. For survival analyses, the end-point used was retransplantation-free survival in addition to excluding HLTx (n = 10), assessed by Cox regression and Kaplan-Meier. RESULTS: ABO-compatible patients had a median of 49 days (2–641), and ABO-identical patients had a median of 89 days (1–1717) (p = 0.048) on the transplant waiting list. Patients with a limited survival up to 1-year showed significant difference in survival rate for ABO-compatible recipients compared to ABO-identical recipients (p < 0.05), however no significant difference was shown in overall survival between the two groups (p > 0.05), with the same pattern shown in patients with a limited survival rate up to ten years, emphysema-patients, when excluding single-LTx and patients transplanted before 2005 and after 2005, respectively (p > 0.05). CONCLUSION: Recipients who received ABO-compatible matched grafts showed a similar survival rate to recipients who received ABO-identical matched grafts in the present study. Cytolomegalovirus and Ebstein Barr Virus mismatch were also identified as risk factors particular among emphysema patients. Since ABO-identical transplantations and ABO-compatible transplantations showed similar results, the present selection-bias of preferring ABO-identical lungs could be adjusted to increase organ allocation. It might also be possible to shorten recipient waiting list time, as an identical match showed over 80% higher time on the waiting list than a compatible, non-identical match. BioMed Central 2019-01-28 /pmc/articles/PMC6350378/ /pubmed/30691526 http://dx.doi.org/10.1186/s13019-019-0846-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Fakhro, Mohammed
Larsson, Hillevi
Malmsjö, Malin
Algotsson, Lars
Lindstedt, Sandra
ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation
title ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation
title_full ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation
title_fullStr ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation
title_full_unstemmed ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation
title_short ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation
title_sort abo-identical matching has no superiority in long-term survival in comparison to abo-compatible matching in lung transplantation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350378/
https://www.ncbi.nlm.nih.gov/pubmed/30691526
http://dx.doi.org/10.1186/s13019-019-0846-6
work_keys_str_mv AT fakhromohammed aboidenticalmatchinghasnosuperiorityinlongtermsurvivalincomparisontoabocompatiblematchinginlungtransplantation
AT larssonhillevi aboidenticalmatchinghasnosuperiorityinlongtermsurvivalincomparisontoabocompatiblematchinginlungtransplantation
AT malmsjomalin aboidenticalmatchinghasnosuperiorityinlongtermsurvivalincomparisontoabocompatiblematchinginlungtransplantation
AT algotssonlars aboidenticalmatchinghasnosuperiorityinlongtermsurvivalincomparisontoabocompatiblematchinginlungtransplantation
AT lindstedtsandra aboidenticalmatchinghasnosuperiorityinlongtermsurvivalincomparisontoabocompatiblematchinginlungtransplantation